## <u>REMARKS</u>

In the Notice to Comply, the Examiner stated the definition of "Xaa" in SEQ ID NOS: 5, 10, 11 and 14 should read "unknown amino acid," and the sequences set out as SEQ ID NOS: 18, 20, 22 and 24 should be presented in 5' to 3' direction. The substitute sequence listing submitted herewith correct these informalities and does not add new matter to the application. Also enclosed is a statement confirming that the content of the paper and computer readable copies of the sequence listing submitted herewith are the same and do not add new matter.

The Examiner also stated that all the sequences recited in the claims should be identified by the appropriate sequence identification number. In the foregoing amendment, claims 127, 128, 135, 136, 142 and 143 were amended to add the appropriate sequence identification numbers. These amendments do not add new matter to the application. The amendments to the claims were made solely to put the claims in better compliance with the sequence rules set out in 37 C.F.R. §§ 1.821-1.825.

No fee is believed to be due with the filing of this paper. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/40451C. A duplicate copy of this paper is enclosed.

Dated: March 14, 2005

Respectfully submitted,

Shafon M. Sintich/ Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant